eUpdate – Cancer of the Prostate Treatment Recommendations

eUpdate – Cancer of the Prostate Treatment Recommendations

Published: 28 September 2017. Authors: ESMO Guidelines Committee

Note: Other eUpdates may have been published for these guidelines. All currently valid eUpdates can be accessed from the page displaying the full guidelines on this topic

Clinical Practice Guidelines

This update refers to the Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Parker C., Gillessen S., Heidenreich A. et al. Ann Oncol 2015; 26 (Suppl 5): v69-v77.

Section

Management of advanced/metastatic disease

Text update

Two phase III trials have compared ADT alone versus ADT plus abiraterone and prednisolone in men with metastatic, hormone-naive disease.  The LATITUDE trial included men with high risk metastatic disease.  Based on 406 events, abiraterone/prednisone improved overall survival (HR: 0.62, 95% CI: 0.51-0.76) [1].  The STAMPEDE trial included men with metastatic and non-metastatic disease.  Based on 446 events, abiraterone/prednisone improved overall survival (HR: 0.63, 95% CI: 0.52-0.76) [2].

Recommendations

  • ADT plus abiraterone/prednisone may be considered as first-line treatment for metastatic, hormone-naive disease [I, A].

References

  1. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. Fizazi et al. N Engl J Med. 2017 Jul 27;377(4):352-360
  2. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. James et al. N Engl J Med. 2017 Jul 27;377(4):338-351